Novavax NVAX announced that the FDA granted emergency use authorization (EUA) to an updated version of its protein-based COVID-19 vaccine for individuals aged 12 years and older. Following this nod, Novavax’s updated vaccine is the only non-mRNA vaccine option available to people in the United States.

The FDA granted Emergency Use Authorization to Novavax's updated COVID-19 vaccine for individuals aged 12 and older. The vaccine, included in CDC recommendations, will soon be available nationwide. Novavax's shot targets the JN.

The newest, updated Covid-19 vaccines are now FDA-approved and available, including the mRNA ones from Pfizer-BioNTech and Moderna and the recombinant one from Novavax.

The Food and Drug Administration (FDA) granted emergency use authorization for an updated version of the Novavax COVID-19 vaccine amid the summer surge of infections. The new version of the vaccine “more closely targets” variants circulating nationwide,